Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock
Xeris Biopharma COO Kevin McCulloch recently sold 15,000 shares of the company's common stock on September 1, 2026, at a weighted average price of $8.4872 per share, generating a total transaction value of $127,308. This sale was executed following a pre-established Rule 10b5-1 trading plan, which McCulloch had adopted on September 4, 2025.
The sale price was in line with the current stock price of $8.43, as Xeris Biopharma has delivered a 38% return over the past six months. As a result of this transaction, McCulloch now holds 1,639,208 shares of Xeris Biopharma common stock directly, while his spouse indirectly holds an additional 25,000 shares. McCulloch has disclaimed beneficial ownership of these shares, except for his pecuniary interest.
According to InvestingPro analysis, the stock is currently trading above its Fair Value and is listed on the platform's Most Overvalued list. Investors interested in a deeper understanding of the stock can access the Pro Research Report, which is available for XERS and over 1,400 other US equities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
